Cure8 research brief
If validated, serum osmolality — a routine, low-cost blood measure — could become an additional marker to help identify IBD in certain hospitalized patients with anxiety. This could aid research and possibly improve case-finding in specific clinical settings.
Clinicians and researchers interested in IBD biomarkers, hospital-based clinicians treating patients with anxiety, and adults with IBD or anxiety who follow research on diagnostic markers.
The study examined whether a routine blood measure — serum osmolality — is associated with having IBD among inpatients with anxiety. Higher SOSM (defined in the paper as ≥ 296.71 mOsm/kg) was strongly associated with IBD prevalence after adjustment for confounders, and SOSM ranked highly in an XGBoost feature-importance model.
The finding comes from observational, retrospective data (MIMIC‑IV). The result suggests SOSM might be an inexpensive adjunctive marker to explore further, but it is not evidence that SOSM causes IBD or that measuring it should change clinical care. The authors call for prospective studies to validate the marker before clinical adoption.
Findings come from a retrospective cross-sectional analysis of the MIMIC‑IV database; the authors explicitly note causal inferences cannot be made and recommend prospective validation. The sample includes hospitalized patients with anxiety, which may limit generalizability.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Zhejiang Provincial Natural Science Foundation of China, award LQ23H280015
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Delays in diagnosing IBD are common and can raise the risk of complications, so understanding when to push for testing matters. The article explains tests and differences between IBS and IBD to help people know when to...
A blood antibody (anti-integrin αvβ6) was associated with relapse risk in UC and may help predict who stays in long-term remission, which could affect monitoring and treatment planning.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
